Intriguingly, vaccine-induced immune thrombotic thrombocytopenia (VITT), a rare but serious complication associated with adenoviral vector-based COVID-19 vaccines, also shares immunopathological features with CAC, namely, upregulated platelet activation via anti-platelet factor 4 (PF4) antibodies [8]. This evidence concerns the gene PF4 and COVID-19.